Genome and gene-silencing platforms moved from concept to clearer clinical footing. Prime Medicine received FDA IND approval for PM-647, an in vivo Prime Editor targeting α-1 antitrypsin deficiency, launching the path to first-in-human Phase I/II evaluation of a one-time intravenous infusion. In other nucleic-acid technology efforts, the industry continued to refine enabling development and manufacturing constraints for RNA therapeutics, including strategies aimed at making siRNA formulations more suitable for home dosing and high-concentration delivery. Separately, regulatory and pipeline milestones for gene therapies also continued to widen. Mirum Pharmaceuticals’ FDA approval expanded treatment options for an ultra-rare soft tissue disease, showing regulators continue to bring gene-targeted therapeutics through fast-moving approval pathways. For developers, the combined message is that editing modality progress is accelerating—paired with more pragmatic formulation/manufacturing plans needed to translate lab performance into scalable therapy.